Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > 01643 MODERN CHI MED > Detailed Quotes

01643 MODERN CHI MED

Watchlist
0.5200.0000.00%
Market Close  02/07 16:08 CCT
High
0.530
Open
0.520
Turnover
149.31K
Low
0.510
Pre Close
0.520
Volume
288.00K
Market Cap
312.00M
P/E(TTM)
3.04
52wk High
0.843
Shares
600.00M
P/E(Static)
3.11
52wk Low
0.400
Float Cap
312.00M
Bid/Ask %
-1.36%
Historical High
1.383
Shs Float
600.00M
Volume Ratio
5.65
Historical Low
0.400
Dividend TTM
0.017
Div Yield TTM
0.017
P/B
0.70
Dividend LFY
3.27%
Div Yield LFY
3.27%
Turnover Ratio
0.05%
Amplitude
3.85%
Avg Price
0.518
Lot Size
3000
Float Cap
312.00M
Bid/Ask %
-1.36%
Historical High
1.383
Shs Float
600.00M
Volume Ratio
5.65
Historical Low
0.400
Dividend TTM
0.017
P/B
0.70
Dividend LFY
3.27%
Turnover Ratio
0.05%
Amplitude
3.85%
Avg Price
0.518
Lot Size
3000
Price Forecast

News

Comment

Sign in to post a comment

    No comment yet

    Company Overview More
    Hyundai Traditional Chinese Medicine Group Co., Ltd. is one of the pioneers in the modernization of traditional Chinese medicine in China. Our main subsidiary, Chengde Omuro Jindan Pharmaceutical Co., Ltd., is a proprietary Chinese medicine pharmaceutical company with a long history. Our development history can be traced back to 1986. Adhering to the corporate mission of “building the national traditional Chinese medicine industry and focusing on the healthy development of national traditional Chinese medicine”, we have always focused on the innovative development of qi and blood supplements, cardiovascular and cerebrovascular drugs, digestive system, proprietary gynaecological medicines, COVID-19, and/or similar conditions (starting in FY2020). We have 71 drug approval numbers and produce 59 types of proprietary Chinese medicine products. Of these, 45 products are included in the “National Medical Insurance Drug Catalogue”. It is a leading manufacturer of proprietary Chinese medicine pills and cardiovascular and cerebrovascular proprietary Chinese medicine capsules in Northeast China. We have major product groups such as Qi and Blood Double Supplement Pills, Kidney Supplement Pills, Shanmei Capsules, Jinqui Kidney Qi Pills, Xinan Capsules, Flavoured Xiaoyao Pills, Flavoured Agastache Zhengqi Pills, Qingfeng Detox Pills, and Liver Protectors. Among them, the three major products of kidney filling pills, qi and blood double supplement pills, and Shanmei capsules occupy leading positions in the market. We have implemented a strict quality control system, established a sound enterprise management system and various operating rules, built a first-class management, production and distribution elite team, and achieved standardized enterprise management. We promote enterprise development through research and development, and have signed cooperation agreements with Heilongjiang University of Traditional Chinese Medicine and Chengde Medical College to jointly develop new drugs and strengthen our product expertise. The company's main product, Shanmei capsule, is an original research drug. It was issued a new drug certificate by the Ministry of Health of China in 1995. It was listed as a second-level protected traditional Chinese medicine by the China Drug Administration. In 2016, it was awarded the title of a famous brand product for small and medium-sized enterprises in Hebei Province by the Hebei Provincial Department of Industry and Information Technology. Based on our geography and our own advantages, we are based in Hebei and are deeply involved in the North China and Northeast China markets while vigorously expanding the East China, South China, Southwest and Northwest China markets, gradually building an efficient marketing network covering the whole country. After years of development, we have established a unique brand advantage. “Omuro” brand products are trusted by many customers due to their competitiveness and diverse combinations, and have always enjoyed a good reputation in the national pharmaceutical market. Entering the 21st century, the company formulated a “grouping, intensification and internationalization” development direction, with the aim of striving to build a domestic first-class, internationally renowned large-scale traditional Chinese medicine pharmaceutical group.
    CEO: Wei Xie
    Market: Hong Kong motherboard
    Listing Date: 01/15/2021
    Paper Trade More
    Direction
    Buy
    Sell
    Types
    LMT Order
    Price
    QTY
    Amount
    --
    Hot List
    TradeSearchNews
    SymbolLatest price%Chg

    Loading...

    Watchlist